Estrella Immunopharma, Inc. (ESLA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Estrella Immunopharma reported revenue of $0. Net income was -$13.1M, or -$0.35 per diluted share. Operating activities generated -$1.8M of cash, leaving -$1.8M of free cash flow. At fiscal year end, Estrella Immunopharma held $3.2M in total assets against $13.5M in total liabilities, including $1.4M of cash and equivalents.
Open the full interactive Estrella Immunopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Estrella Immunopharma Key Stats
| Share Price | $0.31 |
|---|---|
| Market Cap | $13.5M |
| 52-Week Range | $0.31 – $3.05 |
| Shares Outstanding | 43.0 million (basic, 2026 Q2) |
Estrella Immunopharma Income Statement
| FY 2021 | FY 2022 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | $0 | $0 | — | — |
| Gross Profit | $0 | $0 | — | — |
| Operating Income | -$249,146 | -$1.6M | -$7.3M | -$13.1M |
| Pre-Tax Income | -$247,718 | -$915,456 | -$7.3M | -$13.1M |
| Income Tax | $0 | $80,648 | $1,625 | $838 |
| Net Income | -$247,718 | -$996,104 | -$7.3M | -$13.1M |
| Diluted EPS | -$0.21 | -$0.16 | -$0.27 | -$0.35 |
Estrella Immunopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.8M | -$613,174 | -$2.3M | -$2.3M |
| Diluted EPS | -$0.13 | -$0.02 | -$0.05 | -$0.05 |
Estrella Immunopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $478,868 | $40,802 | $4.2M | $1.4M |
| Current Assets | $616,034 | $52,427 | $4.5M | $1.7M |
| Total Assets | $45.8M | $9.7M | $4.5M | $3.2M |
| Current Liabilities | $73,154 | $1.1M | $180,701 | $13.5M |
| Total Liabilities | $1.6M | $2.7M | $180,701 | $13.5M |
| Shareholders' Equity | -$1.0M | -$2.3M | $4.3M | -$10.4M |
Estrella Immunopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$316,158 | -$1.0M | -$16.1M | -$1.8M |
| Cash From Investing | -$45.2M | $36.2M | $5.0M | — |
| Cash From Financing | $46.0M | -$35.6M | $12.8M | $2.3M |
| Free Cash Flow | — | — | — | -$1.8M |
Figures from Estrella Immunopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Estrella Immunopharma financials page for every line item.
Estrella Immunopharma Company Profile
| Ticker | ESLA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Emeryville, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001844417 |
Frequently Asked Questions
What was Estrella Immunopharma's revenue in fiscal 2025?
Estrella Immunopharma (ESLA) reported revenue of $0 for fiscal 2025.
What is Estrella Immunopharma's annual revenue history?
Estrella Immunopharma's annual revenue by fiscal year: 2021: $0; 2022: $0; 2024: $0; 2025: $0.
What was Estrella Immunopharma's net income in fiscal 2025?
Estrella Immunopharma reported net income of -$13.1M for fiscal 2025.
What was Estrella Immunopharma's earnings per share (EPS) in fiscal 2025?
Estrella Immunopharma's diluted EPS was -$0.35 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Estrella Immunopharma generate in fiscal 2025?
Estrella Immunopharma generated -$1.8M of free cash flow in fiscal 2025.
What was Estrella Immunopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Estrella Immunopharma reported revenue of $0.
How many shares of Estrella Immunopharma are outstanding?
Estrella Immunopharma reported a weighted average of 43.0 million basic shares outstanding in 2026 Q2.
What is Estrella Immunopharma's market cap?
Based on its latest closing price, Estrella Immunopharma (ESLA) has a market capitalization of about $13.5M.
When does Estrella Immunopharma's fiscal year end?
Estrella Immunopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Estrella Immunopharma headquartered?
Estrella Immunopharma lists its business address in Emeryville, California in its SEC filings.
Estrella Immunopharma Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →